| Name | Title | Contact Details |
|---|
Aware Health is a B2B partner that delivers modern solutions to self-insured employers to contain orthopedic claims costs.
Shiseido Cosmetics America Ltd. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Shiseido Cosmetics America Ltd. is based in New York, NY. You can find more information on Shiseido Cosmetics America Ltd. at www.sca.shiseido.com
LakeWood Health Center consists of the following four divisions: care center, clinic, hospital, and public health.. They service a population of 6,000 to 9,000 people, the number fluctuating with seasonal tourism activities. LakeWood is a federally designated Critical Access Hospital. As a Catholic non-profit organization, LakeWood Health Center is located in Baudette, Minnesota, and is owned and operated by Catholic Health Initiatives of Denver, Colorado. Our staff serve the social, health and welfare needs of the residents in Lake of the Woods County; contiguous counties, Koochiching, Beltrami, and Roseau; and neighboring Canada.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Medexcel Usa Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in New Windsor, NY. To find more information about Medexcel Usa Inc., please visit www.medexcelusa.com